U.S. Markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,816.90
    -18.90 (-1.03%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1871
    -0.0025 (-0.2137%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • Vix

    18.24
    +0.54 (+3.05%)
     
  • GBP/USD

    1.3906
    -0.0051 (-0.3685%)
     
  • USD/JPY

    109.6150
    +0.1540 (+0.1407%)
     
  • BTC-USD

    41,739.25
    +1,700.86 (+4.25%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters

·1 min read
  • Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab.

  • CEO Severin Schwan declined to speculate on the outcome of the talks, Reuters reported.

  • The accelerated approval of Biogen’s Aduhelm has opened the door to the approval of Alzheimer’s drug candidates on the strength of surrogate endpoints.

  • Roche dismissed the analyst report, stating it is focused on its phase 3 and engaging in discussions with the FDA “when appropriate.” Schwan has told reporters from publications, including Reuters, that Roche is talking to the FDA.

  • Roche will complete a Phase-3 trial of the medicine in 2H of 2022.

  • “There is a continued dialogue with the FDA. I wouldn’t be able to speculate what the outcome of this dialogue will be,” he said. “Our trial is a well-designed, very comprehensive trial, so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease, so let’s keep fingers crossed.”

  • Earlier today, Roche announced half-yearly sales increased by 8% Y/Y to CHF 30.7 billion as demand for COVID-19 tests recovered.

  • Price Action: RHHBY shares are down 3.2% at $46.55 during the market session on the last check Thursday.

  • Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.